Strs Ohio Sells 6,300 Shares of MaxCyte, Inc. (NASDAQ:MXCT)

Strs Ohio lessened its holdings in MaxCyte, Inc. (NASDAQ:MXCT) by 5.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 114,900 shares of the company’s stock after selling 6,300 shares during the period. Strs Ohio owned approximately 0.11% of MaxCyte worth $540,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. Willis Investment Counsel bought a new stake in MaxCyte in the fourth quarter worth $2,585,000. Blair William & Co. IL boosted its stake in MaxCyte by 94.4% during the third quarter. Blair William & Co. IL now owns 251,851 shares of the company’s stock worth $786,000 after buying an additional 122,326 shares during the period. Maven Securities LTD purchased a new position in MaxCyte during the third quarter worth $637,000. Alberta Investment Management Corp boosted its stake in MaxCyte by 13.0% during the third quarter. Alberta Investment Management Corp now owns 199,823 shares of the company’s stock worth $623,000 after buying an additional 23,011 shares during the period. Finally, M&T Bank Corp boosted its stake in MaxCyte by 3.4% during the third quarter. M&T Bank Corp now owns 163,513 shares of the company’s stock worth $510,000 after buying an additional 5,443 shares during the period. Institutional investors own 68.81% of the company’s stock.

MaxCyte Trading Up 0.5 %

Shares of MXCT opened at $3.71 on Friday. The firm has a market capitalization of $387.31 million, a P/E ratio of -10.03 and a beta of 1.34. MaxCyte, Inc. has a 12-month low of $2.45 and a 12-month high of $5.55. The firm has a fifty day moving average price of $4.21 and a 200-day moving average price of $4.33.

MaxCyte (NASDAQ:MXCT) last issued its earnings results on Tuesday, March 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.05. The firm had revenue of $15.67 million during the quarter, compared to analyst estimates of $15.60 million. MaxCyte had a negative net margin of 91.85% and a negative return on equity of 15.90%. Analysts predict that MaxCyte, Inc. will post -0.53 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have commented on MXCT. BTIG Research dropped their price objective on shares of MaxCyte from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, March 13th. Stephens reaffirmed an “overweight” rating and set a $11.00 price objective on shares of MaxCyte in a research note on Tuesday, April 23rd. Finally, William Blair reaffirmed an “outperform” rating on shares of MaxCyte in a research note on Wednesday, March 13th.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.